drugset / Trial / NCT07063693
ABY-029 Glioma Trial
Phase 1
Recruiting
33 enrolled
Dartmouth-Hitchcock Medical Center
Dartmouth College · collabNational Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach brain tumors so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.
Timeline
- Start
- 2026-02-17
- Primary completion
- 2028-07-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABY-029 | Peptide | — | Intravenous |